Trials / Completed
CompletedNCT01031186
First Time in Human Study
A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers
Detailed description
To evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK356278 and may assess the effect of food on GSK356278 pharmacokinetics. They study will assess the compound's effect on nausea, emesis and alertness. Close monitoring of cardiovascular parameters will be included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK356278 | GSK356278 |
| DRUG | PLACEBO | PLACEBO |
Timeline
- Start date
- 2009-11-23
- Primary completion
- 2010-04-07
- Completion
- 2010-04-07
- First posted
- 2009-12-14
- Last updated
- 2017-07-27
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01031186. Inclusion in this directory is not an endorsement.